Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Internal Medicine | Critical Care | Emergency Medicine | Nursing | Journal

Back to Journal Articles

No 30-Day Mortality Reduction With Intraaortic Balloon Pump

Last Updated: August 29, 2012.

 

Findings in patients expected to undergo revascularization for MI with cardiogenic shock

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In patients with cardiogenic shock complicating acute myocardial infarction, for whom early revascularization strategy is planned, intraaortic balloon counterpulsation does not significantly lower 30-day mortality, according to a study published online Aug. 27 in the New England Journal of Medicine to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

WEDNESDAY, Aug. 29 (HealthDay News) -- In patients with cardiogenic shock complicating acute myocardial infarction, for whom early revascularization strategy is planned, intraaortic balloon counterpulsation does not significantly lower 30-day mortality, according to a study published online Aug. 27 in the New England Journal of Medicine to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

Holger Thiele, M.D., from the University of Leipzig-Heart Center in Germany, and colleagues conducted a multicenter, randomized trial in which patients with cardiogenic shock complicating acute myocardial infarction were assigned to intraaortic balloon counterpulsation (IABP group; 300 patients) or to a control group (298 patients). Early revascularization by either percutaneous coronary intervention or bypass was expected in all patients.

The researchers found that, at 30 days, 39.7 percent of patients in the IABP group and 41.3 in the control group had died (relative risk with IABP, 0.96; P = 0.69). For secondary end points or in-process-of-care measures (time to hemodynamic stabilization, intensive care unit length of stay, serum lactate levels, renal function, and dose and duration of catecholamine therapy) there were no significant differences between the groups, nor were there any significant differences for safety assessments (major bleeding, peripheral complications, sepsis, and stroke).

"In this large, randomized trial involving patients with cardiogenic shock complicating acute myocardial infarction, for whom early revascularization was planned, intraaortic balloon pump support did not reduce 30-day mortality," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Maquet Cardiopulmonary, which together with Teleflex Medical provided unrestricted grants for the research.

Abstract
Full Text
Editorial
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Highest Cardiovascular Mortality for Normal BMI, Central Obesity Next: High Midlife Fitness Levels Linked to Healthier Old Age

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.